ArticleBritish journal of cancer2012
FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Effect of food intake on 92 oncological biomarkers by the Proseek Oncology II panel.BMC research notes · 2019Trial
- Cellular Dynamics of Fas-Associated Death Domain in the Regulation of Cancer and Inflammation.International journal of molecular sciences · 2024Review
- Prognostic significance and immune correlates of FADD in penile squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2023Article
- The PANoptosis-related signature indicates the prognosis and tumor immune infiltration features of gliomas.Frontiers in molecular neuroscience · 2023Article
- A Dual Role for FADD in Human Precursor T-Cell Neoplasms.International journal of molecular sciences · 2022Article
- FADD as a key molecular player in cancer progression.Molecular medicine (Cambridge, Mass.) · 2022Review
- Analyzing integrated network of methylation and gene expression profiles in lung squamous cell carcinoma.Scientific reports · 2022Article
- Overexpression of FADD and Bcl-XS proteins as novel prognostic biomarkers for surgically resected non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- AK2 Promotes the Migration and Invasion of Lung Adenocarcinoma by Activating TGF-β/Smad PathwayFrontiers in pharmacology · 2021Article
- Cell-Penetrable Peptide-Conjugated FADD Induces Apoptosis and Regulates Inflammatory Signaling in Cancer Cells.International journal of molecular sciences · 2020Article
- Article
- Association between ANGPTL-4 and the proinflammatory process in cancer cachexia patients.Oncotarget · 2019Article
- Review
- Prognostic value of biomarkers EpCAM and αB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.BMC cancer · 2019Article
- The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding.Cell death & disease · 2019Article
- Foxo3a-dependent miR-633 regulates chemotherapeutic sensitivity in gastric cancer by targeting Fas-associated death domain.RNA biology · 2019Article
- Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma?European respiratory review : an official journal of the European Respiratory Society · 2017Review
- A multiplex platform for the identification of ovarian cancer biomarkers.Clinical proteomics · 2017Article
- Article
- FAS system deregulation in T-cell lymphoblastic lymphoma.Cell death & disease · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe need to unfold the underlying mechanisms of lung cancer aggressiveness, the deadliest cancer in the world, is of prime importance. Because Fas-associated death domain protein (FADD) is the key adaptor molecule transmitting the apoptotic signal delivered by death receptors, we studied the presence and correlation of intra- and extracellular FADD protein with development and aggressiveness of non-small cell lung cancer (NSCLC).
methodsFifty NSCLC patients were enrolled in this prospective study. Intracellular FADD was detected in patients' tissue by immunohistochemistry. Tumours and distant non-tumoural lung biopsies were cultured through trans-well membrane in order to analyse extracellular FADD. Correlation between different clinical/histological parameters with level/localisation of FADD protein has been investigated.
resultsFas-associated death domain protein could be specifically downregulated in tumoural cells and FADD loss correlated with the presence of extracellular FADD. Indeed, human NSCLC released FADD protein, and tumoural samples released significantly more FADD than non-tumoural (NT) tissue (P=0.000003). The release of FADD by both tumoural and NT tissue increased significantly with the cancer stage, and was correlated with both early and late steps of the metastasis process.
conclusionThe release of FADD by human NSCLC could be a new marker of poor prognosis as it correlates positively with both tumour progression and aggressiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.